Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form 4

NovaBay Pharmaceuticals, Inc. Form 4 March 30, 2009

March 30, 20)09											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									OMB APPROVAL			
	UNITED	STATES		ITIES A hington,			NGE	COMMISSIO	N OMB Number:	3235-	0287	
Check thi if no long	or		_ ~	~~~~					Expires:	Januar	y 31, 2005	
subject to Section 1 Form 4 or	AENT O	F CHANGES IN BENEFICIAL OW SECURITIES					VNERSHIP OF	Estimated burden ho	Estimated average burden hours per response			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type R	Responses)											
Wicks Tony D.S. Symbo			Symbol	Name and				5. Relationship of Reporting Person(s) to Issuer				
	NovaBay Pharmaceuticals, Inc. [NBY]					(Check all applicable)						
(Last)	ast) (First) (Middle) 3. Date of (Month/Date)				ansaction			X_ Director10% Owner Officer (give titleOther (specify below) below)				
C/O 5980 H STREET, SU	03/26/2009					Delow) Delow)						
				endment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 				
EMERYVILLE, CA 94608 Form filed by More than One Reporting Person												
(City)	(State)	(Zip)	Table	e I - Non-D	erivative	Securi	ities Ac	equired, Disposed	of, or Benefici	ally Owned	ı	
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)	Executio any	Execution Date, if		3.4. SecuritiesTransactionAcquired (A) orCodeDisposed of (D)(Instr. 8)(Instr. 3, 4 and 5)			SecuritiesFBeneficially(IOwnedIn	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
				Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(
										By the T D. Wick	S	
Common Stock	03/26/2009			А	1,357	A	\$0	156,854	Ι	and Ann Wicks Revocab Trust		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	7. Titl Amou Under Securi (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationsh					
1	Director	10% Owner	Officer	Other			
Wicks Tony D.S. C/O 5980 HORTON STREET SUITE 550 EMERYVILLE, CA 94608	Х						
Signatures							
/s/ Theresa Granados, Attorney Wicks		03/30/2009					
**Signature of Report		Date					
Explanation of Responses:							

If the form is filed by more than one reporting person, *see* Instruction 4(b)(v). *

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.